author-photo

Henry H. Hsu

Plexxikon

12

Papers

637

Citations

Citation Trend

Filter By

Papers (9) Sort By

Journal Conference Others

Results from Phase 1 Extension Study Assessing Pexidartinib Treatment in 6 cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT

2021 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Abstract 2020: Identification of abnormal CSF1 transcripts in tenosynovial giant cell tumors and dose-dependent increase in plasma CSF1 levels in response to pexidartinib treatment

2020 Clinical Trials
Show All
- Source
- Cite
- Save
Citations (0)
A phase 1/2 study of the oral FLT3 inhibitor pexidartinib in relapsed/refractory FLT3-ITD-mutant acute myeloid leukemia.

2020 Blood Advances
Show All
- Source
- Cite
- Save
Citations (11)
Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study

2016 Neuro-oncology
Show All
- Source
- Cite
- Save
Citations (273)
Patient-reported Symptoms of Tenosynovial Giant Cell Tumors

2016 Clinical Therapeutics
Show All
- Source
- Cite
- Save
Citations (40)
Patient-reported outcome instruments meaningful and relevant for tenosynovial giant cell tumor (TGCT): A qualitative study.

2015 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor

2015 The New England Journal of Medicine
Show All
- Source
- Cite
- Save
Citations (284)
A pilot study of PLX3397, a selective colony-stimulating factor 1 receptor (CSF1R) kinase inhibitor, in pigmented villonodular synovitis (PVNS).

2014 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (10)
A phase 2 study of orally administered PLX3397 in patients with recurrent glioblastoma.

2014 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (10)